Variantyx snags $20m Series C
Variantyx, a provider of a genome sequencing-based testing program that diagnoses genetic disorders, has secured $20 million in Series C funding.
Variantyx, a provider of a genome sequencing-based testing program that diagnoses genetic disorders, has secured $20 million in Series C funding.
Copyright PEI Media
Not for publication, email or dissemination